Telmisartan
From Pharmacopedia
More actions
Telmisartan
Micardis
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hypertension0, Cardiovascular risk reduction in selected high-risk patients (ONTARGET-derived label)0
Pharmacy
Starting dose
40 mg PO once daily; titrate to 80 mg
Preparations
20, 40, 80 mg tablets
US FDA Max
80 mg/d
Pharmacology
Routes
Oral
Onset
BP effect within 1-2 weeks
Duration
24 hours
Half-life
~24 hours (longest of the ARB class; suits patients with morning BP surge)[1]
Bioavailability
42-58% (oral; dose-dependent)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Telmisartan is a selective AT1 angiotensin-II receptor antagonist with partial PPAR-γ agonism at therapeutic concentrations; the latter contributes to favorable metabolic effects (lipid handling, glucose tolerance) that distinguish it modestly within the ARB class.0 The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Micardis (telmisartan), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020850s039lbl.pdf